Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| CJC-1295 (with DAC) | GHK (without copper) | |
|---|---|---|
| Category | Peptides | Peptides |
| Standard Dose | Research indicates 2 mg administered once weekly via subcutaneous injection. | Research indicates 1-3% concentration in topical formulations. Injectable dosing follows GHK-Cu protocols at 1-2 mg daily. |
| Timing | Evening administration preferred (aligns with natural GH pulsatility). Inject on an empty stomach — food (especially carbohydrates) blunts GH release. | Topical application morning and evening. Injectable in evening. |
| Cycle Duration | 12-24 week cycles with 4-8 week breaks between cycles. | Topical use can be ongoing indefinitely. Injectable cycles 8-12 weeks. |
| Evidence Level | moderate_human | moderate_human |
CJC-1295 with DAC (Drug Affinity Complex) is a synthetic 30-amino acid GHRH analog with four amino acid substitutions rendering it resistant to DPP-IV proteolytic inactivation. The DAC moiety covalently binds to endogenous serum albumin via a disulfide bond after injection, extending half-life to 5.8-8.1 days. It stimulates pulsatile GH release from anterior pituitary somatotrophs through GHRH receptor activation, producing dose-dependent 2-10 fold increases in plasma GH for 6+ days and 1.5-3 fold IGF-1 elevations for 9-11 days per injection.
Research indicates 2 mg administered once weekly via subcutaneous injection.
Evening administration preferred (aligns with natural GH pulsatility). Inject on an empty stomach — food (especially carbohydrates) blunts GH release.
12-24 week cycles with 4-8 week breaks between cycles.
GHK (glycyl-L-histidyl-L-lysine) is a naturally occurring tripeptide found in human plasma, saliva, and urine that has an extremely high affinity for copper(II) ions. Even without exogenously complexed copper, GHK rapidly chelates available copper in biological systems, making copper-free GHK functionally similar to GHK-Cu in vivo. The peptide stimulates collagen and glycosaminoglycan synthesis, modulates metalloproteinase activity, resets gene expression patterns toward a healthier state (affecting 31.2% of human genes), and activates wound healing cascades.
Research indicates 1-3% concentration in topical formulations. Injectable dosing follows GHK-Cu protocols at 1-2 mg daily.
Topical application morning and evening. Injectable in evening.
Topical use can be ongoing indefinitely. Injectable cycles 8-12 weeks.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →